Volume 72, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645


To assist the Peruvian Ministry of Health in modifying the malaria treatment policy for their north Pacific coastal region, we conducted an efficacy trial of sulfadoxine-pyrimethamine (SP) and SP plus artesunate (SP-AS) for the treatment for uncomplicated infections. A total of 197 patients were randomized to therapy with either SP (25 mg/kg of the sulfadoxine component in a single dose on day 0) or a combination of SP plus AS (4 mg/kg on days 0, 1, and 2) and were followed for 28 days for symptoms and recurrence of parasitemia. No statistically significant differences between the two groups were observed on enrollment with respect to age, sex, history of malaria, or geometric mean parasite density. A total of 185 subjects completed the 28-day follow-up. Of the 91 subjects treated with SP alone, two had recurrences of parasitemia on day 7 and one on day 21. Of the 94 subjects treated with SP-AS, one had a recurrence of parasitemia on day 21. Fever and asexual parasite density decreased significantly more rapidly and the proportion of patients with gametocytemia on days 3–28 was significantly lower in subjects treated with combination therapy than in those who received SP alone. No severe adverse drug reactions were observed; however, self-limited rash and pruritis were significantly more common and an exacerbation of nausea, vomiting, and abdominal pain were observed significantly more frequently among patients who had received SP-AS. These results have contributed to a National Malaria Control Program decision to change to SP-AS combination therapy as the first-line treatment for uncomplicated malaria in northern coastal Peru in November 2001, making Peru the first country in the Americas to recommend this combination therapy.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. White NJ, 1998. Preventing antimalarial drug resistance through combinations. Drug Resist Updates 1 : 3–9. [Google Scholar]
  2. White NJ, Nosten F, Looareesuwan S, Watkins WM, Marsh K, Snow RW, Kokwara G, Ouma J, Hien TT, Molyneux ME, Taylor TE, Newbold CI, Ruebush TK II, Danis M, Greenwood BM, Anderson RM, Olliaro P, 1999. Averting a malaria disaster. Lancet 353 : 1965–1967. [Google Scholar]
  3. WHO, 1998. The Use of Artemisinin and Its Derivatives as Anti-Malarial Drugs: Report of a Joint CTD/DMP/TDR Informal Consultation. Geneva: World Health Organization. WHO Document WHO/MAL/98.1086
  4. Nosten F, van Vugt M, Price R, Luxemburger C, Thway KL, Brockman A, McGready R, ter Kuile F, Looareesuwan S, White NJ, 2000. Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Lancet 356 : 297–302. [Google Scholar]
  5. White NJ, 1997. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Agents Chemother 41 : 1413–1422. [Google Scholar]
  6. Price RN, Nosten F, Luxemburger C, ter Kuile FO, Paiphun L, Chongsuphajaisiddhi T, White NJ, 1996. Effects of artemisinin derivatives on malaria transmissibility. Lancet 347 : 1654–1658. [Google Scholar]
  7. Doherty F, Sadiq AD, Bayo L, Alloueche A, Olliaro P, Milligan P, von Seidlein L, Pinder M, 1999. A randomized safety and tolerability trial of artresunate plus sulfadoxine-pyrimethamine versus sulfadoxine-pyrimethamine alone for the treatment of uncomplicated malaria in Gambian children. Trans R Soc Trop Med Hyg 93 : 543–546. [Google Scholar]
  8. von Seidlein L, Jawara M, Coleman R, Doherty T, Walraven G, Targett G, 2001. Parasitaemia and gametocytaemia after treatment with chloroquine, pyrimethamine/sulfadoxine, and pyrimethamine/sulfadoxine combined with artesunate in young Gambians with uncomplicated malaria. Trop Med Int Health 6 : 92–98. [Google Scholar]
  9. von Seidlein L, Milligan P, Pinder M, Bojang K, Anyalebechi C, Gosling R, Coleman R, Ude JI, Sadiq A, Duraisingh M, Warhurst D, Alloueche A, Targett A, McAdam K, Greenwood B, Walraven G, Olliaro P, Doherty T, 2000. Efficacy of artesunate plus pyrimethamine-sulphadoxine for uncomplicated malaria in Gambian children: a double-blind, randomised, controlled trial. Lancet 355 : 352–357. [Google Scholar]
  10. Marquiño W, MacArthur JR, Barat LM, Oblitas FE, Arrunátegui M, Garavito G, Chafloque ML, Pardavé B, Gutierrez S, Arróspide N, Carrillo C, Cabezas C, Ruebush TK II, 2003. Efficacy of chloroquine, sulfadoxine-pyrimethamine, and mefloquine for the treatment of uncomplicated Plasmodium falciparum malaria on the north coast of Peru. Am J Trop Med Hyg 68 : 120–123. [Google Scholar]
  11. Ministerio de Salud, Peru, 1999. Política Nacional de Medicamentos para el Control de la Malaria en el Perú. Lima: MINSA.
  12. Bruce-Chwatt LJ, Black RH, Canfield CJ, Clyde DR, Peters W, 1986. Chemotherapy of Malaria. World Health Organization Monograph Series No. 27, Geneva: World Health Organization.
  13. Pan American Health Organization, 1998. Evaluation of the Therapeutic Efficacy of Drugs for the Treatment of Uncomplicated Plasmodium falciparum Malaria in the Americas. Washington, DC: Pan American Health Organization. OPS/HCP/HCT/113/98.
  14. Ministry of Public Health, Thailand, 1996. Post-Registration Surveillance of the Artemisinin Derivatives Used Operationally in Thailand. Nonthaburi, Thailand: Technical Division, Food and Drug Administration.
  15. Ribiero IR, Olliaro P, 1998. Safety of artemisinin and its derivatives: a review of published and unpublished clinical trials. Med Trop (Mars) 58 : 50–53. [Google Scholar]
  16. Botero D, Restrepo M, Montoya A, 1985. Prospective double-blind trial of two different doses of mefloquine plus pyrimethamine-sulfadoxine compared with pyrimethamine-sulfadoxine alone in the treatment of falciparum malaria. Bull World Health Organ 3 : 731–737. [Google Scholar]
  17. Reyes S, Osanai CH, Costa Passos AD, 1986. Resistência in vivo do Plasmodium falciparum as 4-aminoquinoleínas e á associação sulfadoxina-pirimetamina. II. Estudio de Manaus, Amazonas 1983–1984. Rev Bras Mal Doencas Trop 38 : 37–44. [Google Scholar]
  18. Osorio LE, Giraldo LE, Grajales LF, Arriaga AL, Andrade AL, Ruebush TK, Barat LM, 1999. Assessment of the therapeutic response of Plasmodium falciparum to chloroquine and sulfadoxine-pyrimethamine in an area of low malaria transmission in Colombia. Am J Trop Med Hyg 61 : 968–972. [Google Scholar]
  19. Nwanyanwu OC, Ziba C, Macheso A, Kazembe P, 2000. Efficacy of sulphadoxine-pyrimethamine for acute uncomplicated malaria due to Plasmodium falciparum in Malawian children under five years old. Trop Med Int Health 5 : 355–358. [Google Scholar]
  20. White NJ, 1992. Antimalarial drug resistance: the pace quickens. J Antimicrob Agents Chemother 30 : 571–585. [Google Scholar]
  21. Watkins WM, Mosobo M, 1993. Treatment of Plasmodium falciparum malaria with PSD: selective pressure for resistance is a function of long elimination half life. Trans R Soc Trop Med Hyg 87 : 75–78. [Google Scholar]

Data & Media loading...

  • Received : 17 Jul 2003
  • Accepted : 22 Jan 2004

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error